Melanoma vaccine - MedVac

Drug Profile

Melanoma vaccine - MedVac

Latest Information Update: 26 Apr 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator New York University School of Medicine
  • Developer MedVac; New York University School of Medicine
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Malignant melanoma

Most Recent Events

  • 26 Apr 2007 Discontinued - Phase-III for Malignant melanoma in USA (Intradermal)
  • 11 Jul 2000 A clinical study has been added to the Cancer therapeutic trials section
  • 26 Aug 1999 Two studies have been added to the Cancer therapeutic trials section ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top